id: NEW:psychedelic_therapy_lsd_psilocybin_to_NEW:alcohol_abstinence_reduction
name: Psychedelic Therapy (LSD/Psilocybin) â†’ Alcohol Abstinence or Substantial Reduction
  in Drinking
from_node:
  node_id: NEW:psychedelic_therapy_lsd_psilocybin
  node_name: Psychedelic Therapy (LSD/Psilocybin)
to_node:
  node_id: NEW:alcohol_abstinence_reduction
  node_name: Alcohol Abstinence or Substantial Reduction in Drinking
direction: positive
category: behavioral
mechanism_pathway:
- 'Step 1: Administration of psychedelic substances (LSD or psilocybin) in controlled
  therapeutic settings induces altered states of consciousness and neuroplasticity'
- 'Step 2: Psychedelic experience facilitates psychological insights, emotional processing,
  and disruption of maladaptive cognitive patterns associated with alcohol dependence'
- 'Step 3: Enhanced self-awareness and mystical-type experiences promote motivation
  for behavioral change and reduced craving for alcohol'
- 'Step 4: Sustained neurobiological and psychological effects lead to increased odds
  of achieving abstinence or substantial reduction in alcohol consumption'
evidence:
  quality_rating: A
  n_studies: 6
  primary_citation: 'Dakota J. Sicignano et al. 2023. The impact of psychedelics on
    patients with alcohol use disorder: a systematic review with meta-analysis. Current
    Medical Research and Opinion.'
  supporting_citations: []
description: Meta-analysis of 6 trials demonstrates that psychedelic therapy (LSD
  or psilocybin) enhances the odds of achieving alcohol abstinence or substantial
  reduction in drinking by 89% compared to control conditions. When restricted to
  rigorous randomized, double-blind, placebo-controlled trials (n=4), the odds ratio
  was 2.16. The mechanism involves psychedelic-induced neuroplasticity and psychological
  insights that facilitate behavioral change in patients with alcohol use disorder.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 1.89
    type: odds_ratio
    ci_lower: 1.42
    ci_upper: 2.5
  p_value: null
  sample_size: null
moderators:
- name: Study design rigor
  direction: strengthens
  strength: moderate
  description: Double-blind, placebo-controlled trials showed stronger effect (OR
    2.16) compared to less rigorous designs (OR 1.89)
- name: Type of psychedelic
  direction: strengthens
  strength: weak
  description: Both LSD and psilocybin showed similar positive effects; psilocybin
    trial from 2022 was of higher methodological quality
